Kyle Moran - 08 Dec 2025 Form 4 Insider Report for Wave Life Sciences Ltd. (WVE)

Role
Chief Financial Officer
Signature
/s/ Kyle Moran
Issuer symbol
WVE
Transactions as of
08 Dec 2025
Net transactions value
-$2,564,559
Form type
4
Filing time
10 Dec 2025, 21:45:05 UTC
Previous filing
06 Feb 2025
Next filing
11 Feb 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Moran Kyle Chief Financial Officer C/O WAVE LIFE SCIENCES LTD.,, 733 CONCORD AVE., CAMBRIDGE /s/ Kyle Moran 10 Dec 2025 0001657765

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction WVE Ordinary Shares Options Exercise $169,800 +60,000 +67% $2.83 149,218 08 Dec 2025 Direct F1
transaction WVE Ordinary Shares Sale $792,000 -60,000 -40% $13.20 89,218 08 Dec 2025 Direct F1
transaction WVE Ordinary Shares Options Exercise $314,000 +100,000 +112% $3.14 189,218 08 Dec 2025 Direct F1
transaction WVE Ordinary Shares Sale $750,000 -50,000 -26% $15.00 139,218 08 Dec 2025 Direct F1, F4
transaction WVE Ordinary Shares Sale $660,000 -50,000 -36% $13.20 89,218 08 Dec 2025 Direct F1
transaction WVE Ordinary Shares Options Exercise $237,500 +50,000 +56% $4.75 139,218 08 Dec 2025 Direct F1
transaction WVE Ordinary Shares Sale $900,000 -50,000 -36% $18.00 89,218 08 Dec 2025 Direct F1
transaction WVE Ordinary Shares Options Exercise $294,120 +36,000 +40% $8.17 125,218 09 Dec 2025 Direct F1
transaction WVE Ordinary Shares Sale $729 -36 -0.04% $20.25 89,218 09 Dec 2025 Direct F1, F6
transaction WVE Ordinary Shares Options Exercise $524,000 +50,000 +56% $10.48 139,218 09 Dec 2025 Direct F1
transaction WVE Ordinary Shares Sale $1,001,250 -50,000 -36% $20.02 90,365 09 Dec 2025 Direct F1, F6, F7

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction WVE Share Option (right to buy) Award $0 -60,000 -100% $0.000000 0 08 Dec 2025 Ordinary Shares 60,000 $2.83 Direct F2
transaction WVE Share Option (right to buy) Award $0 -100,000 -57% $0.000000 75,000 08 Dec 2025 Ordinary Shares 100,000 $3.14 Direct F3
transaction WVE Share Option (right to buy) Award $0 -50,000 -18% $0.000000 222,700 08 Dec 2025 Ordinary Shares 50,000 $4.75 Direct F5
transaction WVE Share Option (right to buy) Award $0 -36,000 -100% $0.000000 0 09 Dec 2025 Ordinary Shares 36,000 $8.17 Direct F2
transaction WVE Share Option (right to buy) Award $0 -50,000 -100% $0.000000 0 09 Dec 2025 Ordinary Shares 50,000 $10.48 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 13, 2025.
F2 These share options are fully vested.
F3 The share option represented a right to purchase a total of 175,000 ordinary shares that vest as to 25% of the shares on January 1, 2023 and vests as to an additional 6.25% of the shares quarterly thereafter until January 1, 2026.
F4 The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $15.00 to $15.045 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.
F5 The share option represented a right to purchase a total of 272,200 ordinary shares that vest as to 25% of the shares on February 17, 2024 and vests as to an additional 6.25% of the shares quarterly thereafter until February 17, 2027.
F6 The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $20.00 to $20.22 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.
F7 Includes 1,147 ordinary shares acquired on July 14, 2025, under the issuer's 2019 Employee Share Purchase Plan.